New Products In Brief
This article was originally published in The Tan Sheet
Executive Summary
Bausch + Lomb updates AREDS formula: Due to hit shelves in May, PreserVision Eye Vitamin and Mineral Supplement AREDS2 formula aims to support eye health and prevent age-related macular degeneration. Bausch + Lomb says April 9 the PreserVision line extension includes omega-3 fatty acids and the carotenoids lutein and zeaxanthin, as used in the ongoing second Age-Related Eye Disease Study. The Madison, N.J., firm suggests a retail price of $29.99 for 60 soft gels. The results from the original National Institutes of Health-sponsored Age-Related Eye Disease Study were released in 2001; AREDS2 completed patient enrollment in 2008 (1"The Tan Sheet" Nov. 3, 2008)
You may also be interested in...
In Brief
Pfizer promotes Advil Congestion Relief
SupplySide West In Brief
AREDS II rolling: Enrollment is complete and the second iteration of the National Eye Institute's Age-Related Eye Diseases Study is under way, according to Paul S. Bernstein, a researcher and professor of ophthalmology and visual sciences at the University of Utah School of Medicine's John A. Moran Eye Center. At the SupplySide West trade show in Las Vegas Oct. 22, Bernstein said through 2013, AREDS II will follow 4,000 patients between the ages of 50 and 85 with high risk for age-related macular degeneration at 100 U.S. sites. He explained that the antioxidant formulation for the first AREDS was "based on the best science of the 1980s" and omitted lutein and zeaxanthin, but the AREDS II formulation includes those carotenoids at levels about five times greater than a typical American diet. The revised formulation also lowers the original zinc and beta-carotene levels due to concerns about urinary tract problems and lung cancer, respectively. The AREDS results, released in 2001, showed high-dose antioxidant vitamins and minerals reduce the risk of advanced AMD progression by 25 percent (1"The Tan Sheet" Jan. 21, 2008, p. 14)
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC